Patient treatment and cohorts
death, tumor, toxicity, Tumors, TNBC
DISEASE PROGRESSION, TUMOR, TUMORS, EVENTS, APPENDIX
Eligible patients were enrolled in the TNBC cohort or HR+/HER2− cohort according to estrogen receptor (ER), progesterone receptor (PR), and HER2 status determined using the most recent biopsy. Tumors expressing ER and PR, defined as ≥ 1% of tumor cells staining positive by immunohistochemistry (IHC), were considered hormone receptor-positive [All patients received pamiparib 60 mg orally twice daily (PO BID) in 28-day, continuous cycles until disease progression as assessed by investigator, unacceptable toxicity, death, withdrawal of consent, loss to follow-up, or trial termination by the sponsor. Pamiparib was administered with or without food. Dose modifications of pamiparib included dose reductions and dose interruptions; these modifications were not mutually exclusive. Treatment with pamiparib could be reduced by one dose level to 40 mg PO BID, or by two dose levels to 20 mg PO BID; a maximum of two dose reductions was permitted. Pamiparib was permitted to be withheld by the investigator for up to 28 consecutive days for medical events (or 56 days for anemia).After treatment discontinuation, all patients were followed up for safety, survival, and further anticancer therapy. A graphical representation of the study design is available in the Supplementary Appendix (Supplementary Fig. S1).